Despite treatment advancements with the introduction of HDMTX and rituximab, up to half of patients will have disease relapse, and 10%–15% may have primary refractory disease.

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

The biologic DMARDs rituximab and abatacept were associated with an increased risk for incident cancers in patients with RA ...

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Eli Lilly's BRUIN CLL-321 trial shows pirtobrutinib improves outcomes in CLL/SLL patients, offering longer progression-free ...

Incyte (INCY) announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab, a humanized Fc-modified ...